Comparison of Once- Versus Twice-Daily Administration of long-acting insulin Detemir in children with type 1 diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181106041574N1

Enrollment

Registered

2019-01-16

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 1. Type 1 diabetes mellitus without complications

Interventions

Intervention 1: Intervention group: The insulin used is (Levemir®

NovoNordisk A / S, Bagsvaerd, Denmark, 100 U / ml). For patients, the schedule is once a day for insulin Detemir plus a short-acting insulin for food.The whole study period is 4 months. The first mont

NovoNordisk A / S, Bagsvaerd, Denmark, 100 U / ml). For patients, the schedule is twice a day for insulin Detemir plus a short-acting insulin for food.The whole study period is 4 months. The first mon

Eligibility

Sex/Gender

All

Age

24 Months to No maximum

Inclusion criteria

Inclusion criteria: Diabetes mellitus type 1 (according to ISPAD 2014 criteria) Age at diagnosis: 2-6 years old Lasting at least 1 year since diagnosis Desire to use insulin Detemir

Exclusion criteria

Exclusion criteria: The use of drugs that are effective on controlling diabetes

Design outcomes

Primary

Measure	Time frame
HbA1c. Timepoint: 3 Months. Method of measurement: lab.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Tavakolizadeh

Tehran University of Medical Sciences

rtavakolizadeh@sina.tums.ac.ir+98 21 5517 6814

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026